149 terminated. 149 Phase 2, 19 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 149 | Terminated 149 |
| Phase 1 | 19 | Terminated 19 |
| Phase 3 | 7 | Terminated 7 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Rocatinlimab, Placebo - Asthma | Phase 2 | Terminated | Amgen | 317 | 2024-05-24 | 2026-08-11 |
| A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease HRG2005 inhalation, Placebo to match HRG2005 inhalation, Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 82 | 2024-01-15 | 2025-12-22 |
| Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo - Uncontrolled Asthma | Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 517 | 2023-11-26 | 2025-12-18 |
| Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Leflunomide tablet - Musculoskeletal Disease Other, GVHD, Chronic | Phase 2 | Terminated | Tata Memorial Centre | 1 | 2023-09-18 | 2025-09-10 |
| Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Amlitelimab, Placebo - Asthma | Phase 2 | Terminated | Sanofi | 335 | 2023-09-05 | 2026-10-02 |
| Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma RPT193, Placebo - Asthma | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 38 | 2023-07-05 | 2026-03-23 |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| Treatment of Pneumocystis in COPD (the TOPIC Study) Trimethoprim Sulfamethoxazole, Placebo - COPD Exacerbation Acute | Phase 1 / Phase 2 | Terminated | Corewell Health East | 1 | 2022-09-28 | 2023-11-29 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| A Phase II Clinical Trial of TQC3721 Suspension for Inhalation TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 59 | 2022-05-20 | 2025-04-20 |
| A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma AK120, Placebo - Asthma | Phase 2 | Terminated | Akeso | 1 | 2022-02-11 | 2022-10-12 |
| A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications Azithromycin, HP xenon (¹²⁹XE) - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Genentech, Inc. | 12 | 2021-11-16 | 2024-12-24 |
| Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant Ruxolitinib - Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO) | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 7 | 2021-11-12 | 2026-04-07 |
| Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma CSJ117, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 136 | 2021-09-08 | 2022-10-10 |
| A Study to Test if TEV-53275 is Effective in Relieving Asthma TEV-53275 Dose A, TEV-53275 Dose B, Placebo - Asthma | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 97 | 2021-05-04 | 2023-06-08 |
| Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids AZD1402, Placebo, Short acting beta agonist (SABA) (rescue medication) - Asthma | Phase 2 | Terminated | AstraZeneca | 72 | 2021-03-12 | 2025-08-28 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 RESP301 - COPD, Bronchiectasis | Phase 2 | Terminated | Thirty Respiratory Limited | 88 | 2021-03-01 | 2025-01-31 |
Showing 20 of 149. Sign in to see all of them.
Asthma (57) · Pulmonary Disease, Chronic Obstructive (56) · Bronchiolitis Obliterans Syndrome (32) · Bronchiolitis Obliterans (6) · Graft vs Host Disease (5) · Emphysema (4) · Bronchiectasis (3) · Bronchiolitis (3) · Lung Diseases (3) · Pulmonary Emphysema (3) · Respiratory Sounds (3) · Status Asthmaticus (3) · Bronchitis, Chronic (2) · Dyspnea (2) · Hypersensitivity (2)
Respiratory Tract Diseases (148) · Lung Diseases (146) · Bronchial Diseases (99) · Immune System Diseases (88) · Pathological Conditions, Signs and Symptoms (66) · Pathologic Processes (60) · Chronic Disease (59) · Disease Attributes (59) · Hypersensitivity, Immediate (57) · Respiratory Hypersensitivity (57) · Hypersensitivity (55) · Bronchitis (41) · Bronchiolitis (36) · Organizing Pneumonia (33)
Azithromycin (6) · Fluticasone (6) · itacitinib (5) · INCB039110 (4) · Roflumilast (4) · Epinephrine (3) · Rituximab (3) · ibrutinib (3) · Cholecalciferol (2) · Formoterol Fumarate (2) · Inhalation (2) · Lenalidomide (2) · N-(1-(3-chloro-4-hydroxyphenyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl)-N'-((2-((3-(2-((2-hydroxyethyl)thio)phenyl)-1,2,4-triazolo(4,3-a)pyridin-6-yl)thio)phenyl)methyl)-urea (2) · Oxygen (2) · Prednisone (2)
Novartis Pharmaceuticals (13) · Merck Sharp & Dohme LLC (6) · GlaxoSmithKline (5) · AstraZeneca (4) · Boehringer Ingelheim (4) · Pfizer (4) · Aeris Therapeutics (3) · FLUIDDA nv (3) · Incyte Corporation (3) · M.D. Anderson Cancer Center (3) · MedImmune LLC (3) · Actelion (2) · Amgen (2) · Amphastar Pharmaceuticals, Inc. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)
United States (82) · United Kingdom (30) · Canada (28) · Germany (26) · Poland (20) · France (14) · Spain (13) · Belgium (12) · Argentina (10) · Hungary (10) · Italy (10) · South Korea (10) · Australia (9) · Czechia (9) · Netherlands (8)
Francesco Blasi, MD (2) · Gebhard Wagener, MD (2) · Joseph Parker, M.D. (2) · Wilfried De Backer, M.D., M.S. (2) · Alessio Fasano, M. D. (1) · Amin Alousi, MD (1) · Anne E Dixon, MD (1)
PMID 19213793, PMID 19460848, PMID 20025989, PMID 21356110, PMID 21917440, PMID 21945511, PMID 22586006, PMID 23900970, PMID 23949578, PMID 24995515, PMID 25389139, PMID 25695403, PMID 26416925, PMID 28146642, PMID 32150492, PMID 32840597, PMID 33032168, PMID 33314326, PMID 34265047, PMID 34326185, PMID 35781099, PMID 36735745, PMID 37011709, PMID 37698881, PMID 38485149, PMID 39393433, PMID 40311075
2018 (5), 2008 (3), 2014 (3), 2015 (3), 2017 (3), 2019 (3), R01HL131960 (2), 2005 (1), 2009 (1), 2023 (1), P01AT002647 (1), P30CA016056 (1), P30CA042014 (1), P50CA090440 (1), R01HL096471 (1)